The gastrointestinal tract and gastrokines, together with novel systems such as the endocannabinoid system and the intracellular mTOR pathway, represent promising pharmacological targets for the development of therapies against obesity. This evidence concerns the gene MTOR and obesity due to melanocortin 4 receptor deficiency.